Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus

This article was originally published in The Pink Sheet Daily

Executive Summary

Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.

You may also be interested in...

CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications

First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.

Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion

After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.

GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal

Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts